Keep up with the pace of infectious diseases

Infectious Disease research is a dynamic space requiring nimble and innovative solutions. Our team of infectious diseases and vaccines experts respond to the need for speed and flexibility through novel trial design and technology solutions that allow for real-time data delivery.

Expedited protocols and proven success.

COVID may have been unprecedented, but our vaccine experience, sit solutions, systems, process, tools and support meant we were ready, and will continue to be.

• 400k direct-to-patient
• 105K+ patients enrolled in vaccine trials within 4-6 weeks per trial
• 1.7X meaningfully high inclusion of diverse populations enrolled in COVID-19 vaccine trials versus peers

Revolutionizing global pandemic response speeds

Our advanced analytics includes real-time simulation of active cases, near real time surveillance and impact analysis. Plus, expertise in influenza and COVID-19, clinical trial acceleration and advance response time and vaccine development. We have diverse teams with experience in over 400 trials in more than 90 countries, excluding COVID-19 trials, in the last 10 years.

Facts

Community engagement IQVIA continues to work with partners around the world in supporting Community Health Workers with improved training, education, and support services for better public health. Capacity building Infectious Diseases continue to disproportionately impact people living in low and middle income countries. At IQVIA we work to expand our footprint to meet the healthcare needs across diverse markets. Global footprint We operate in 100+ countries, establishing a true global footprint. Innovation for speed IQVIA Decentralized Trials are leading the way to overcome some of the most common challenges in clinical research. We're pushing the boundaries of what's possible with full-service hybrid decentralized trial solutions. Learn how IQVIA can deliver value for you and your patients today. Megatrials experience In the past ten years IQVIA has provided clinical services for 21 Phase I to IV, pivotal and registration megatrials (defined as >10,000 participants). In total we have recruited more than 490,000 participants in 121 countries worldwide.

Experience and expertise

It is an increasingly diverse and dynamic environment with new and re-emerging pathogens. The study of infectious diseases and vaccines is as complex as the populations and environments they impact. Timing of treatment and protection is critical for seasonal preparedness or pandemic relief. Our global IQVIA specialized team of scientific, medical, and operational experts can design and deliver complex clinical trials by

• Strategizing adaptive trial designs
• Overcoming recruitment barriers and obstacles
• Enhancing productivity at investigative sites
• Utilizing tailored solutions to accelerate timelines without sacrificing data quality

Strategies and solutions for every trial

IQVIA supports sponsors of every size and at every stage, including government and nonprofit organizations, to advance broader public health goals. IQVIA is a Global Health Clinical Consortium partner and has conducted BARDA, NIH, and CEPI funded trials. We have delivered trials in disease areas from influenza, anthrax, and Ebola to acute radiation syndrome and nerve agent countermeasures. We understand clinical development challenges and offer strategies and solutions to address your specific and unique trial needs.